Podcast•Mar 5, 2026•39 min
Episode 192: Ken and Dawn Weigh in on ChatGPT, Ketamine, Urolithin-A, Rapamycin, and More in Wide-Ranging AMA
In this AMA episode, host Dawn Cornegas and IHMC CEO Dr. Ken Ford field listener questions on a wide array of topics, from astronaut training in NASA's Neutral Buoyancy Lab to the latest research on supplements like urolithin‑A and anti‑aging drugs such as rapamycin. Ken explains how neutral buoyancy simulates weightlessness for spacewalk rehearsals, discusses promising proof‑of‑concept trials showing urolithin‑A can rejuvenate immune function in middle‑aged adults, and reviews early human data suggesting low‑dose rapamycin improves cardiac and endothelial health in older men. He also critiques a controversial Yale study on ketamine and mTOR, highlighting the need for more robust evidence.
